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ABSTRACT
Objectives: The safety and efﬁcacy of sevelamer hydro-
chloride in binding phosphate in patients with end-stage
renal disease and its ability to attenuate the progression of
cardiac calciﬁcation have been well documented but not
the longer-term health and economic implications. Thus,
a model of the predicted long-term consequences of seve-
lamer compared with calcium-based binders (acetate and
carbonate) was developed.
Methods: Long-term cardiovascular implications of
1 year of treatment with phosphate binders in patients
on hemodialysis are estimated based on the patient’s
demographics, comorbidities, and physiologic and renal
parameters. The initial calciﬁcation score and expected
changes over 1 year are derived using regression equa-
tions developed from the Treat-to-Goal study and trans-
lated to cardiovascular disease risk based on equations
developed from a long-term cohort study. In this article,
the implications of cardiovascular disease for life expect-
ancy and medical costs are accounted for from a US payer
perspective.
Results: The cardioprotective effect of sevelamer over
1 year is estimated to result in a 12% reduction in cardi-
ovascular events compared with calcium acetate. In a
population of 100 patients, the savings of $205,600
accrued due to avoiding nine cardiovascular events with
sevelamer, largely offset the increased binder costs, lead-
ing to a favorable cost-effectiveness ratio of about $2200
per (discounted) life-year gained.
Conclusions: Although both binders provide equivalent
phosphate binding capacity, the results indicate that the
advantage of 1 year of treatment with sevelamer in atten-
uating the progression of calciﬁcation has important
clinical and economic consequences, suggesting that this
provides good value for money.
Keywords: cardiovascular events, cost-effectiveness, end-
stage renal disease, phosphate binders.
Introduction
Chronic renal failure is a functional diagnosis char-
acterized by a progressive decrease in glomerular ﬁl-
tration rate, eventually reaching end-stage renal
disease (ESRD) requiring dialysis or transplantation
for the patient’s survival. In 2001, there were more
than 360,000 patients in the United States with
ESRD and the number of patients needing chronic
dialysis has been increasing at a rate of 9% per year
[1,2]. These patients suffer cardiovascular events
more frequently than expected and this has been
shown to be associated with both atherosclerotic
plaques and stiffening of arterial walls [3]. Because
coronary calcium is frequently seen in these athero-
sclerotic lesions, its detection has been taken to be
the direct imaging of atherosclerosis [4]. Although
still controversial, evidence supporting the inde-
pendent predictive value of imaging with electron
beam tomography (EBT) has been accumulating in
the general population [5–11].
There is compelling evidence of increased preva-
lence of cardiac calciﬁcations in ESRD, especially
after long-term dialysis, but the precise pathogene-
sis and clinical signiﬁcance remain to be elucidated
[12,13]. Several factors likely contribute to the pre-
disposition to widespread calciﬁcation in ESRD.
Some of these risk factors are the well-established
ones associated with coronary artery disease in the
general population (e.g., hypertension, diabetes,
dyslipidemia), whereas others are speciﬁc to ESRD
patients. The metabolic abnormalities present in
ESRD lead to an increasingly disordered calcium
and phosphate metabolism. As renal function dete-
riorates, calcium excretion is impaired and excess
calcium is transported into cellular and interstitial
compartments. Although this helps maintain cal-
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cium homeostasis, it predisposes the patient to vas-
cular calciﬁcation [14]. This process is exacerbated
in those on hemodialysis by calcium absorption
from dialysate, abnormalities in bone buffering and
turnover, and ingestion of calcium-based phosphate
binders to treat hyperphosphatemia [15]. The
hypothesis that the process of calciﬁcation may be
favorably altered by using a noncalcium based
binder is supported by several studies that have
found that the amount of calcium ingested daily as
a phosphate-binding agent is signiﬁcantly associ-
ated with higher vascular calciﬁcation scores [16–
18].
In 1998, sevelamer hydrochloride (Renagel), a
nonmetal, noncalcium polymer that binds preferen-
tially to phosphate through ion exchange and
hydrogen bonding in the duodenum, was shown to
be safe and effective in binding phosphate in
patients on hemodialysis [19]. More recently, seve-
lamer has also been shown to attenuate the progres-
sion of coronary and aortic calciﬁcation—evaluated
using EBT—over a 1-year period relative to calcium
binders (Treat-to-Goal [TTG] study) [20,21].
In this article, we present a clinical-economic
model that brings together the best available infor-
mation on the risks associated with calciﬁcation
over the longer term and their clinical and economic
consequences to advance a more rigorous and com-
plete understanding of the choice of phosphate
binder. The analyses presented here are speciﬁc to
the United States, but the model is designed to be
applicable in a variety of health-care systems
around the world. The customized analyses facili-
tated by this model should allow decision-makers to
assess the consequences associated with the choice
of phosphate binder for their particular patient
population or setting, while remaining within the
bounds of the efﬁcacy demonstrated in the TTG
study.
Methods
Disease Simulation Model Overview
The main model modules and key linkages are
shown in Figure 1. In essence, the selection of phos-
phate binder and patient characteristics at the start
of treatment drive the changes in calciﬁcation score
expected over the course of 1 year. The impact of
these 1-year changes on cardiovascular risk, as well
as on the clinical and economic sequelae, is esti-
mated in the ﬁnal module.
The model functions as an individual patient sim-
ulation, implemented using discrete event simula-
tion—a modeling technique that permits the course
of disease and its management to be conceptualized
in terms of the events that happen and the impact
these have on the patients and other components of
the system [22,23]. All relevant aspects can be
incorporated explicitly and efﬁciently, and the entire
model can be presented very transparently. In a dis-
crete event simulation, there is no speciﬁc cycle
length. That is, time passes speciﬁc to the experience
of a particular patient at a given point in time. This
permits ﬂexibility and efﬁciency not allowed by
other modeling approaches.
A schematic representation of the model struc-
ture is provided in Figure 2. At the start, a patient
with ESRD is assigned characteristics based on
prespeciﬁed distributions for demographics, physi-
ologic parameters, renal parameters and comorbid-
ities. The initial calciﬁcation score (EBT Agatston
score [24]) is also assigned. These assignments take
place by weighted random sampling of the distribu-
tions. An identical copy of each patient is then
Figure 1 Relationship among the key
modules of the Disease Simulation
Model. CVD, cardiovascular disease.
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created. This is done to ensure that factors other
than type of phosphate binder do not create nui-
sance variance—it is equivalent to carrying out an
identical twin study. One of the twins is assigned
sevelamer treatment and the other a calcium-based
binder (i.e., as if there were perfect treatment ran-
domization). The changes in cardiac calciﬁcation,
physiologic and renal parameters expected to occur
given the patient’s assigned treatment are then
derived using regression equations developed from
the TTG study. For these analyses, three sets of
calculations were done corresponding to 1 year of
treatment with sevelamer, and with each of the two
calcium-based binders.
The long-term—up to lifetime—implications of
these 1-year changes in calciﬁcation and other
parameters are then estimated in terms of the occur-
rence of cardiovascular disease, which is simulated
based on the patients’ calciﬁcation score and other
characteristics at the end of the treatment year. Dur-
ing this time, cardiovascular disease events are
counted and management costs are accumulated.
The implications of cardiovascular disease for life
expectancy are also accounted for. The base case
analysis is expressed over 13 years because the
majority of patients have died by then. Cost and
beneﬁts occurring beyond 1 year are discounted at
3% per year. The modeling process is replicated for
a hypothetical cohort of 10,000 patients. The cal-
culations are carried out using ARENA, a software
package that facilitates discrete event simulations
coded in SIMAN language [25].
Treatment Effect Module
The effect of phosphate binders on the progression
of coronary and aortic calciﬁcation has been docu-
mented in TTG using EBT technology. Changes in
EBT calciﬁcation scores over time are therefore the
main drivers of the treatment effect in the model. To
enable application of the TTG study ﬁndings to
populations with ESRD differing from those of
TTG in terms of demographics and disease charac-
teristics, regression analyses were conducted to pre-
dict changes in calciﬁcation by treatment group
over the course of 1 year, rather than directly imple-
menting the changes observed in the trial. A two-
part model was developed for that purpose. First, a
logistic regression analysis was carried out to pro-
Figure 2 Simpliﬁed structure of the Disease Simulation Model. CVD, cardiovascular disease.
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vide the probability that a patient will have an
increase in calciﬁcation score during the course of
1 year. Then, linear regression analyses were con-
ducted to predict the magnitude of the change in
calciﬁcation score (increase and decrease considered
separately). The ﬁnal models are summarized in
Table 1.
In TTG and other trials, a beneﬁcial effect of
sevelamer on cholesterol lowering has also been
observed [26]. This treatment effect is applied in the
model, assuming no difference between the groups
with respect to the use of cholesterol-lowering treat-
ments, as speciﬁed in the TTG protocol. The impli-
cations of altering this assumption are examined in
sensitivity analyses. Although a beneﬁcial treatment
effect was also observed in terms of oversuppression
of parathyroid hormone, it was not modeled
because of lack of consistent data on the conse-
quences of oversuppression (e.g., fractures). As doc-
umented in the clinical trial, no difference in
phosphate binding capacity is assumed among the
treatment groups (i.e., binder dose is adjusted to
achieve desired binding capacity).
Cardiovascular Disease Risk Module
Survival. A Gompertz function, which has been
shown to be a good estimator of general human
mortality [27], was used to estimate the death haz-
ard over time:
l(t) = - l0egt (1)
where l0 is the hazard at time 0 (beginning of dial-
ysis) and g is the accelerator. Both parameters were
estimated using information from the US Renal
Data System (USRDS) annual report [2], which pro-
vides up to 10-year survival data adjusted for age
for all incident dialysis patients. Duration of life is
not adjusted by quality of life, because of a lack of
data documenting the incremental effect of cardio-
vascular disease on the quality of life of patients
with renal failure.
Cardiovascular  disease  risk  estimator. Patients’
risk for initial and subsequent cardiovascular events
was estimated through implementation of a set of
regression equations developed based on a longitu-
dinal data set of 179 patients with ESRD treated at
one center in France—subgroups of this population
have been used in previous analyses [28]. Patients
entered the data set some time after dialysis start
and follow-up ended at kidney transplant, death,
move, or April 2002. This data set has been
described elsewhere [29]. Brieﬂy, information was
available on calciﬁcation and other patient charac-
teristics (including biochemistry values during the
prior year) and on the occurrence of ﬁve cardiovas-
cular event types over time: congestive heart failure,
coronary artery disease, cerebrovascular disease,
aortic disease, peripheral arterial disease. The EBT
score corresponding to the measured Doppler score
was estimated using an equation derived from TTG
(Table 2).
A Cox proportional hazards analysis was con-
ducted to identify the determinants of cardiovascu-
Table 1 Regression analyses for change in calciﬁcation score over time
Logistic regression
Multiple linear regression 
Ln (EBT increase) Ln (EBT decrease)
b (SE) P value b (SE) P value b (SE) P value
Binder type (sevelamer/calcium) 0.45 (0.18) 0.011
Calcium ¥ Phosphate (mmol2/L2) -0.27 (0.14) 0.062
Albumin (g/L) 0.08 (0.07) 0.272 -0.08 (0.06) 0.206
Ln (EBT) -0.12 (0.06) 0.059 0.34 (0.12) 0.007 1.06 (0.11) <0.0001
Elemental calcium (mg) 1.25E-05 (0.5E-05) 0.015
CVD history (no/yes) -0.32 (0.17) 0.073
Sex (male/female) -0.32 (0.14) 0.035 -0.37 (0.15) 0.018
Race (non-Caucasian/Caucasian) -0.72 (0.17) <0.0001
The logistic regression analysis provides the probability a patient will have an increase in calciﬁcation score during the course of 1 year.  The linear regression equa-
tions predict the magnitude of the change in calciﬁcation score. The smearing estimators to be used when retransforming the predicted log changes are 1.357 for
the increase model and 1.375 for the decrease model. The -2LogL c2 for the logistic regression model is 14 (4 df), P = 0.006. The model F for the increase model
is 10 (5 df), P < 0.0001, R2 = 0.56; for the decrease model 42 (3 df), P < 0.0001, R2 = 0.75.
Table 2 Multiple linear regression analysis predicting the
logarithmically transformed EBT score
Variable b (SE) P value
Age (year) 0.02 (0.01) 0.013
Dialysis vintage (>36 months/£36 months) 0.35 (0.11) 0.002
Serum calcium (mmol/L) 1.42 (0.73) 0.053
Serum phosphate (mmol/L) 0.39 (0.21) 0.061
Total cholesterol (mmol/L) -0.16 (0.10) 0.117
HDL-cholesterol (mmol/L) -0.54 (0.30) 0.077
CVD history (no/yes) -0.70 (0.12) <0.0001
CVD history ¥ age 0.01 (0.01) 0.139
Because the distribution of baseline EBT calciﬁcation scores was quite skewed,
the values were logarithmically transformed to achieve a normal distribution
and permit use of standard parametric statistical tests. The smearing estimator
equals 1.847. The model F is 12 (8 df), P < 0.0001, R2 = 0.40.
CVD, cardiovascular disease.
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lar risk [29]. The ﬁnal regression model includes the
EBT score, diabetes, C-reactive protein levels,
diastolic blood pressure, sex, smoking, hyperten-
sion, and total cholesterol. The individual patient’s
hazard can be derived as:
  =  h0  ¥  HRi (2)
For consistency with the mortality data, a Gom-
pertz function was used to extrapolate this base
hazard over time. The same acceleration parameter
g as for mortality was used. The likelihood of a
cardiovascular event being fatal is based on the
longitudinal data set (22% for an initial and 41%
for a subsequent event). The speciﬁc event type is
hi0
assigned based on the observed distributions
(Table 3). A patient that experiences a fatal event
(cardiovascular or other) is removed from the
model once the respective costs and life-years have
been accumulated. In case of a nonfatal cardiovas-
cular event, the patient’s time-dependent risk of a
subsequent cardiovascular event is estimated using
a Weibull function:
(3)
where g and a are estimated at 0.658 and 941.553
[29,30].
After 1 year, the relevant physiologic parameters
(i.e., calciﬁcation score, total-cholesterol, serum
phosphate, parathyroid hormone) of survivors who
have not suffered an event are updated and the car-
diovascular risk is computed given these new char-
acteristics (Fig. 3).
Costs
The direct medical costs, from the perspective of a
payer providing full health-care coverage in the
United States, are reported in 2002 US dollars.
Where 2002 values were not available, older values
l
g
a a
g
t
t
= ÊËÁ
ˆ
¯˜
-1
Table 3 Event type breakdown for nonfatal and fatal cardi-
ovascular events
Nonfatal events 
Fatal 
events (%)
Initial
(%)
Subsequent
(%)
Peripheral arterial disease 33 50 5
Congestive heart failure 11 11 14
Coronary artery disease 47 32 57
Aortic disease 9 — 5
Cerebrovascular disease — 7 19
Figure 3 Schematic representation of the Cardiovascular Disease Risk Module. CVD, cardiovascular disease; LE, life expectancy; t, time in
model; model t, model time horizon; NF, nonfatal.
Huybrechts et al.554
were  inﬂated  using  the  medical  care  component
of the US Consumer Price Index. Charges were
adjusted by means of a cost-to-charge ratio of 0.61
established by the Massachusetts Ofﬁce of Health
Care Finance and Policy [31].
Hospitalization. Inpatient resource-use data and
costs (all accommodations, special care unit, phar-
macy, laboratory, imaging, diagnostic and surgical
procedures) were derived from all-payer 1999 acute
inpatient hospital discharge databases from Califor-
nia, Florida, Maryland, Massachusetts, and Wash-
ington (Table 4) [32–36]. Cases were identiﬁed by
means of principal ICD-9 diagnosis codes corre-
sponding to the ﬁve cardiovascular events of
interest (congestive heart failure, coronary artery
disease, cerebrovascular disease, aortic disease,
peripheral arterial disease) and secondary diagnosis
of chronic renal failure. Physician resource-use pro-
ﬁles were developed for each diagnosis based on
length of stay, diagnosis and procedure codes, use of
the emergency room and intensive care unit, dialysis
during the hospital stay and discharge status, and
the corresponding costs were calculated using per-
tinent Physicians’ Current Procedural Terminology
codes [37,38].
Subsequent care. For patients discharged home, no
further costs are included. Costs per episode of
home health care ($2494), inpatient rehabilitation
($13,722), skilled nursing facility ($8289), and
intermediate care facility ($34,264) were applied to
the proportions of patients using them [32–36,38–
40].
Medications. The 2002 Wholesale Acquisition
Cost was used as the cost for sevelamer ($1.2799/g)
and calcium acetate ($0.1766/g for PhosLo™
667 mg tabs). The price used for calcium carbonate
equals €10.46 (100 Sertürner 500 mg tabs) [41], or
approximately $0.2054/g. A weighted average daily
cost was calculated for cholesterol-lowering drugs
using the distribution of use observed in TTG:
$3.63 [42].
An overview of the main model parameters and
their source is provided in Table 5.
Validation
To assess the face validity, the model structure was
presented to two scientiﬁc advisory boards, one
consisting of clinical experts from Brazil, France,
the UK, and the United States, and another of econ-
omists experienced in this type of modeling from
Brazil, Germany, the UK, and the United States. To
test the technical validity of the model, validation
analyses were carried out. These involved setting
inputs to extreme values and checking for logical
consistency. In addition, calibration analyses com-
pared the outputs to the inputs from TTG to ensure
that the model faithfully replicated the trial.
Analyses
The characteristics of the patient population used
for the base case are summarized in Table 6. The
base case compares sevelamer with calcium acetate
because this is by far the most widely used calcium-
based binder in the United States. The ﬁndings for
calcium carbonate are explored in a sensitivity anal-
ysis. Apart from estimating the costs and health
consequences of treatment, cost-effectiveness ratios
(CERs) reﬂecting the cost per (discounted) life-year
gained (dLYG) and per cardiovascular event averted
were also derived.
Univariate sensitivity analyses considered the
impact of sevelamer on the progression of calciﬁ-
Table 4 Acute hospital costs and discharge disposition status by analysis population
Acute hospital
costs ($)
Discharge disposition status
Home (%) HHC (%) Rehab facility (%) SNF (%) ICF (%)
Peripheral arterial disease 23,071 43 15 9 26 7
Alive at discharge 22,161
Died in hospital 38,349
Congestive heart failure 11,326 64 17 2 14 3
Alive at discharge 10,723
Died in hospital 16,995
Coronary artery disease 21,247 65 17 3 12 3
Alive at discharge 20,155
Died in hospital 27,923
Aortic disease 45,433 57 14 7 21 1
Alive at discharge 39,394
Died in hospital 83,481
Cerebrovascular disease 11,247 47 14 9 24 6
Alive at discharge 10,456
Died in hospital 16,508
HHC, home health care; ICF, intermediate care facility; SNF, skilled nursing facility.
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cation, the effect of calciﬁcation on cardiovascu-
lar risk, cholesterol-lowering treatment practices,
the treatment cost, the cardiovascular event costs,
the model time horizon, the discount rate, and
future medical costs. An analysis was also con-
ducted to explore how long the risk reduction
afforded by 1 year of treatment would have to last
for a given cost-effectiveness threshold to be met.
Results of multivariate sensitivity analyses are also
presented.
All results are based on 10 replications of 10,000
patients.
Results
Base case
After 1 year of treatment with sevelamer, 36% of
patients are expected to have an increase in EBT,
compared with 57% of those on calcium acetate.
The mean calciﬁcation score decreases from 1502 to
1362 in the sevelamer group compared with an
increase to 1557 in those on calcium acetate. After
1 year, patients treated with sevelamer are thus
expected, on average, to have a 13% lower calciﬁ-
cation score than patients treated with calcium ace-
tate. The results are summarized in Table 7.
In a population of 100 patients, 33 of those
receiving sevelamer are expected to experience an
initial cardiovascular event (fatal: 8), compared
with 37 of those who receive calcium (fatal: 8). A
total of 32 subsequent events (fatal: 13) occur while
on sevelamer treatment, compared with 37 (fatal:
16) on calcium. Sevelamer is thus estimated to pre-
vent a total of nine events, which represents a 12%
reduction in cardiovascular risk. Therefore, 11
patients need to be treated for 1 year to prevent one
cardiovascular event.
The majority of the total cost for each treatment
option is attributable to hospital inpatient manage-
ment of cardiovascular disease (74% for sevelamer;
86% for calcium acetate), followed by subsequent
in- and outpatient care (10% and 11%, respec-
tively). The expense of 1-year of sevelamer therapy
contributes 15% to the overall cost, compared with
2% for calcium. HMG-CoA reductase inhibitors
make up the remaining 2% of the cost in both
groups. As can be seen, the 12% decrease in cardi-
ovascular disease management cost due to avoiding
nine events with sevelamer (savings of $205,600)
largely offsets the increased binder costs, leading to
a favorable CER of less than $2500 per discounted
LYG and around $4500 per event prevented.
Sensitivity analysis
The results improve further when comparing seve-
lamer to calcium carbonate: $1107/dLYG and
$2262 per event prevented; mainly because of the
higher daily calcium consumed by these patients. As
illustrated in Figure 4, the cost-effectiveness of seve-
lamer was very sensitive to the model time horizon.
The CER is $111,000/dLYG at 2 years, drops
quickly to around $50,000/dLYG at 3 years, and
Table 5 Summary description of the main model parameters
Main model parameters Source, ref
Treatment effect
Two-part multivariate regression model to predict changes in EBT over the course of 1 year [20]
Change in physiologic parameters during year of treatment
Linear regression models to predict changes in total cholesterol and parathyroid hormone levels [20]
All patients assumed to achieve target serum phosphate level of 1.776 mmol/L [20]
Non-CVD and all-cause (used to estimate remaining life expectancy for patients alive at the end of the model 
time horizon) mortality 
Gompertz function [2,29]
Risk for initial CVD events
Population base hazard h0 [29]
Individual patient hazard ratio (HRi) derived from Cox proportional hazards model [29]
Gompertz function to extrapolate risk over time [2]
Risk for subsequent CVD events
Weibull function [29]
Proportion of fatal CVD events [29]
CVD event type distribution [29]
Hospitalization costs [32–36,38]
Subsequent care
Location of care on discharge from hospital [32–36]
Costs per episode of home health care, inpatient rehabilitation, skilled nursing facility, intermediate care facility [32–36,38,39,40]
Medications
Renagel and calcium acetate Wholesale Acquisition Cost Genzyme Corporation
Calcium carbonate—Yellow List [41]
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stabilizes at around $2,500/dLYG from year 12
onwards. Another relatively inﬂuential parameter is
the impact of treatment on cardiac calciﬁcation.
Sensitivity analyses were carried out using the 95%
conﬁdence interval (CI) of the b-coefﬁcient for
binder type in the logistic regression equation
predicting increase versus no increase in EBT, as
well as for the dose of elemental calcium in the lin-
ear regression equation predicting the magnitude of
the increase. Use of the lower bound of the 95% CI
results in a CER around $10,000/dLYG when only
one of the coefﬁcients is varied at a time. When both
b-coefﬁcients are changed simultaneously, using the
lower bound of the 95% CI yields a CER around
$20,000/dLYG. Using the upper bound always
results in cost savings making sevelamer dominant
over calcium treatment. When allowing cholesterol-
lowering treatment  practice  to  be  altered  from
the prevailing  practice  in  TTG  by  assuming  that
all patients with an LDL-cholesterol level
>2586 mmol/L (>100 md/dL) will receive treatment
per the K/DOQI guidelines, the CER changes to
$9664/dLYG, mainly driven by the nondifferential
1-year cholesterol levels (i.e., assuming that statin
treatment is at least as effective as sevelamer). The
costs of hospitalizations often vary as a result of fac-
tors such as geographic region, access to health-care
services, and payer. The costs of subsequent care for
patients with ESRD who have suffered a cardiovas-
cular event are difﬁcult to estimate precisely as a
result of lack of data. The stability of the results
when varying the overall event cost—hospital and
subsequent care combined—over a broad range
(50% in either direction) was therefore assessed.
Reducing the management cost by half results in a
net cost of $1407 (CER: $8088/dLYG), whereas
increasing the costs leads to savings of $649. For the
other parameters tested, the CER remained well
below $5000/dLYG.
Although it remains controversial whether to
include future costs for unrelated medical care and
nonmedical expenditures within economic evalua-
tions, some researchers suggest they should be
included on methodological grounds. We examined
this issue using the total Medicare payments for
patients on hemodialysis per patient year at risk as
the estimate for the annual future cost for medical
care [2], and predicted an increase in cost per dLYG
to around $59,000.
Given the need for phosphate binders as long as
patients are on hemodialysis, clinicians and other
decision-makers might legitimately ask about the
longer-term implications of sevelamer use. Until
long-term trial or observational data are available
and there is more insight into the biological mech-
anisms of calciﬁcation and cardiovascular risk, this
cannot be estimated with any conﬁdence. Instead,
we explored the issue by estimating how long the
risk reduction obtained by 1 year of treatment has
to last in order for a given cost-effectiveness thresh-
Table 6 Characteristics of the patient population for the
base case analysis
Patient characteristics*
Mean
or %
Interquartile
range
Demographics
Age (years) 54 40–67
Sex (males) 60%
Race (white) 85%
Smoking (smokers) 6%
Physiologic parameters
Total cholesterol (mmol/L) 4.75 3.95–5.50
HDL cholesterol (mmol/L) 1.16 0.90–1.36
Diastolic blood pressure (mm Hg)
Hypertension 85 74–95
No hypertension 73 64–81
Renal parameters
Serum phosphate (mmol/L) 1.84 1.52–2.15
Serum calcium (mmol/L) 2.34 2.25–2.44
Parathyroid hormone (pg/ml) 318 80–436
Vintage (months)
Diabetes 28 10–24
No diabetes 79 16–120
Comorbidities
Diabetes by age group (year)
£29 0%
30–49 2%
50–64 23%
≥65 18%
Hypertension by sex
Males 80%
Females 63%
CVD history by diabetes and age
Diabetes (year)
£29 0%
30–49 46%
50–64 73%
≥65 88%
No Diabetes (year)
£29 3%
30–49 11%
50–64 31%
≥65 58%
Treatment
Dose sevelamer (mg) 6136 3781–8607
Dose calcium acetate (mg) 4443 2549–5766
Dose calcium carbonate (mg) 3470 2651–4323
Baseline EBT calciﬁcation score 1500 79–1652
*Because the longitudinal data set reﬂects an actual practice of patients on
hemodialysis, which should be more generalizable than a clinical trial popula-
tion, these data were used to deﬁne the population used in the base case anal-
ysis. Only a few exceptions were made. Because the high proportion of
smokers observed in the French data set (51%) was not considered to be an
accurate reﬂection of current smoking habits in the United States, the propor-
tion of smokers observed in TTG was used instead. For consistency, the values
for total cholesterol, HDL cholesterol and parathyroid hormone were also
obtained from TTG. Correlations between the input parameters were formally
assessed in both the longitudinal and TTG data set, and those that were sta-
tistically signiﬁcant and clinically relevant were incorporated in the model. C-
reactive protein (correlated with age and cardiovascular history) and albumin
(correlated with age and C-reactive protein) are not included in the table
because they are derived using regression equations with the intercept sampled
from a normal distribution to recreate the variability observed in the source
data.
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old to be met (Fig. 5). For example, in order for
1 year of treatment with sevelamer to yield a CER
below $25,000/dLYG, the reduction in cardiovas-
cular risk would have to persist for at least
4.3 years. With a threshold of $100,000/dLYG, the
beneﬁt would only have to last for a little over
2 years.
The results of the multivariate sensitivity
analyses are summarized in Figure 6. The cost-
effectiveness acceptability curve represents the
probability that sevelamer is cost-effective at all
possible values of the maximum acceptable CER
appropriate for decision-making. If the ceiling CER
is $2500 per dLYG, there is a 51% chance that
sevelamer is cost-effective. The likelihood of seve-
lamer being cost-effective,  increases  to  95%  with
a  ceiling  ratio  of  $10,000/dLYG.  There  is  a  5%
chance  that  sevelamer  use  would  result  in  cost
savings.  It should be noted that possible structural
changes in the cardiovascular risk functions over
time—reﬂecting uncertainty in the treatment effect
beyond 1 year—are not accounted for in these
multivariate analyses resulting from lack of infor-
mation. There is currently insufﬁcient clinical infor-
mation to permit quantiﬁcation of the likely impact,
even for exploratory  purposes.  Were  these  to  be
Figure 4 Univariate sensitivity analyses.
The solid vertical line represents the
incremental cost-effectiveness of treat-
ment with sevelamer relative the treat-
ment with calcium acetate when all
variables were set at their baseline value.
Horizontal bars indicate the range in
incremental cost-effectiveness ratios
obtained by setting each variable at the
lower and upper limit of its range and
holding all other variables constant at
their baseline value. Incremental cost-
effectiveness ratios less than $0 (dashed
vertical line) indicate that treatment with
sevelamer is cost-saving. (*: shorter time
horizons are not depicted for clarity.
2 years: $111,000; 3 years: $53,000;
4 years: $33,000).
Table 7 Results of the cost-effectiveness analysis (base case)
Sevelamer Calcium acetate Difference
One-year EBT 1,362 1,557 -195
CVD events (per 100 patients): 65 (21 F) 74 (24 F) -9
Peripheral arterial disease 17 (1 F) 20 (1 F) -2
Congestive heart failure 7 (3 F) 8 (3 F) -1
Coronary artery disease 32 (12 F) 36 (14 F) -4
Aortic disease 3 (1 F) 4 (1 F) 0
Cerebrovascular disease 6 (4 F) 7 (5 F) -1
Total costs ($) 18,113 17,734 379
CVD costs ($) 15,045 17,101 -2,056
Hospitalization costs ($) 13,323 15,166 -1,843
Subsequent care costs ($) 1,722 1,935 -213
Statin costs ($) 364 363 0.36
Treatment costs ($) 2,704 270 2,431
Life expectancy (year) 9.19 8.95 0.241
Life expectancy discounted (year) 7.61 7.43 0.178
Incremental cost-effectiveness, $/life-year gained 1,641
Incremental cost-effectiveness, $/discounted life-year gained 2,219
Incremental cost-effectiveness, $/CVD event prevented 4,448
CVD, cardiovascular disease; F, fatal.
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considered, the uncertainty would undoubtedly
increase considerably.
Conclusions
The ability to image and detect calcium deposition
within the vasculature is a recent development.
Thus, much remains to be learned about the impli-
cations of these lesions, particularly their quantita-
tive relation to cardiovascular risk. Nevertheless, it
seems prudent given the evidence accumulating in
various populations to consider it undesirable to
allow calciﬁcation to build. This is particularly
important in patients such as those with ESRD who
are at very high risk for cardiovascular problems.
Clearly, any external factor that further aggravates
the complex metabolic dysfunction that promotes
calciﬁcation in these patients should be viewed with
concern. Because a major contributor is the addi-
tional calcium load due to the use of calcium-based
phosphate binders, the introduction of a safe alter-
native that is inert in this respect is potentially very
attractive. In this article, we examined the cost-
effectiveness of one such option, sevelamer, based
on the assumption that coronary calciﬁcation is a
serious problem exacerbated by exogenous calcium.
In a population of patients with ESRD with a
mean EBT score of 1500, sevelamer is estimated to
prevent a total of about nine cardiovascular events
and to save 18 life-years per 100 patients, at a cost-
effectiveness relative to calcium acetate of less than
$2500/dLYG. These results compare favorably to
those from other economic analyses in both renal
failure and prevention of cardiovascular disease. A
review covering 1968 to 2000 found that the cost-
effectiveness of center hemodialysis ranged from
$55,000 to $80,000 per LYG. It also found that kid-
ney transplantation has become more cost-effective
over time, reaching a plateau at approximately
$10,000 per life-year [43]. Common interventions
for prevention of cardiovascular disease, such as
smoking-cessation programs, use of aspirin, statins
and tissue plasminogen activator, yield CERs rang-
ing from $220 [44] to $32,700 [45] per life-year.
The results should be viewed in light of several
important limitations of the model and the strength
of the supporting data. Most importantly, this is not
a model of homeostatic balance and its sequelae at
the level of the individual patient. The treatment-
speciﬁc changes in calciﬁcation score, renal and
physiologic parameters and their implications for
cardiovascular risk should only be interpreted at a
population level. Data are insufﬁcient to allow for a
detailed simulation of the impact of various treat-
ment regimens on renal homeostasis in a given
patient.
The quantitative link between calciﬁcation and
cardiovascular  risk  is  based  on  the  only  study
that has so far provided longitudinal data on this
in  patients  with  ESRD  [16,28,29,46].  This  link
is consistent, however, with the ﬁndings from
studies done in initially asymptomatic, low- to
intermediate-risk individuals without ESRD [6–10].
For high-risk individuals, the relationship has been
somewhat less clear, but it should be noted that
the validity of this conclusion has been questioned
Figure 5 Analysis of the duration of beneﬁt after 1 year of treat-
ment required for a given cost-effectiveness threshold to be met.
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because of the imaging techniques used in that par-
ticular study [5,47].
The immediate effect achieved with 1 year of
sevelamer treatment is a change in risk, speciﬁcally
cardiovascular disease risk. One possible—and in
fact the easiest—approach would be to stop here
and present this change in risk to decision-makers
as the return for the money spent on sevelamer
treatment for their patients. Nevertheless, it is clin-
ically relevant to try and translate this treatment
effect into outcomes that are important to clinical
and economic decision-makers. This is accom-
plished by examining how the risks will manifest
over time, which is tantamount to integrating the
risk curves. This approach is similar to the one typ-
ically used in cost-effectiveness analyses to translate
the health effects established in clinical trials—
which are nearly always too short-term for estimat-
ing survival—to the change in the full survival curve
[48]. Because it is currently unknown how the abso-
lute risk difference obtained after 1 year of treat-
ment will evolve with continued treatment with
either type of phosphate binder, it would be tenuous
to make any projections about the expected treat-
ment effect in terms of coronary calciﬁcation
beyond TTG’s time horizon—especially in view of
the complex and multifactorial nature of the under-
lying disease processes. By strictly remaining within
the bounds of the efﬁcacy demonstrated in the trial,
the only presumption made about future effect is
that the predictive ability of the calciﬁcation score is
not itself affected by treatment—in other words,
that the impact of a change in score is correctly
reﬂected by the respective failure-time curves for the
two scores. This type of assumption is commonly
required when intermediate outcomes are used
(blood pressure reduction and lipid lowering are
salient examples). Although it seems reasonable to
assume that the outcomes implied by score changes
brought about by treatment will be borne out, only
long-term data can demonstrate this conclusively.
The predicted changes in EBT scores are based on
the only data currently available: one clinical trial in
200 patients. Conﬁdence in the model ﬁndings
would strengthen if the beneﬁcial effect of sevelamer
on arterial calciﬁcation were conﬁrmed in additional
studies, ideally with even longer time horizons.
The economic implications estimated in this
study are conservative in that only acute inpatient
costs and the costs of subacute care provided imme-
diately on discharge from the hospital are included
for the management of cardiovascular events. There
were insufﬁcient data to reliably estimate the incre-
mental costs associated with longer-term outpatient
management of cardiovascular problems in patients
with ESRD who are already receiving intense care.
Consideration of only the cardiovascular implica-
tions associated with the choice of phosphate binder
further contributes to the conservative nature of the
estimates. For example, the consequences in terms
of fractures and vascular access problems are not
included. Indeed, in a study comparing patients on
sevelamer to controls not receiving this binder, a
50% reduction was observed in all-cause ﬁrst hos-
pitalization over 17 months of follow-up leading to
an annual savings of more than $16,500 per
patient, on average [49].
Because the model was implemented as a discrete
event simulation, it provided a means to more real-
istically represent health-care processes and, in turn,
to better address the speciﬁc research questions
posed without forcing the analyst to accept unnec-
essary compromises, which exact a heavy price in
efﬁciency, transparency and credibility [23].
In summary, evidence from a randomized con-
trolled trial has shown that in the treatment of
hyperphosphatemia, the use of sevelamer compared
with calcium acetate moderates valvular and vascu-
lar calciﬁcation [20,21], a known risk factor in
nonuremic individuals and shown to be a strong
predictor of cardiovascular and all-cause mortality
in ESRD [18,28]. Because long-term follow-up data
are not yet available, understanding the implica-
tions of this physiologic effect from a clinical and
economic perspective requires predictive equations.
Development of such a model cannot wait for the
accumulation of follow-up data because payers and
policymakers must decide today whether or not to
make this binder available and individual physi-
cians must make treatment decisions based on the
available evidence. Although subject to the uncer-
tainties inherent in modeling long-term outcomes
based on limited short-term clinical trial results, the
results of this study suggest that sevelamer should
be considered a desirable approach to treating
hyperphosphatemia in patients on hemodialysis and
1 year of treatment with sevelamer provides good
value for money.
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